6Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing [ S ]. Sixteenth informational supplement. M100-S16, CLSI, 2006.
7Plumb J,Holwell D. Group B strep:prevention is better than cure[J]. Pract Midwife,2004,7( 1 ):17-21.
8Binqen E, Leelercq R, Fitoussi F, et al. Emergence of group A Streptococcus strains with different mecha- nisms of macrdide resistance [ J ]. Antimicrob Agents Chemother, 2002, 46(5) : 1199-1203.
5Berardi A,Rossi C, Lugli L, et al. Group B streptococcus late- onset disease: 2003-2010[ J]. Pediatrics,2013,131 :e361-e368.
6Verani JR, McGee L, Schrag SJ, et al. Prevention of perinatal group B streptococcal disease-revised guidelines from CDC, 2010 [ J]. MMWR Recomm Rep, 2010,59 : 1-36.
7Edwards MS. Group B streptococcal conjugate vaccine: a timely concept for which the time has come [ J ]. Hum Vaccin, 2008,4: 444-448.
8Hemmati F, Pishva N. C-reactive protein as an indicator of aqueductal gliosis and hydrocephaly in neonatal meningitis [ J ]. Singapore Med J ,2008,49 :e163-e165.
9Garland SM, Cottrill E, rVlarkowski L, et al. Antimierobial resistance in group B streptococcus: the Australian experience [ J]. J Med Mierobiol,2011,60 Pt 2:230-235.
10Levent F,Baker C J, Rench MA, et al. Early outcomes of group B streptococcal meningitis in the 21st century[ J]. Pediatr Infect Dis J,2010,29 : 1009-1012.
